{"altmetric_id":4335096,"counts":{"readers":{"mendeley":9,"citeulike":0,"connotea":0},"total":{"posts_count":19},"twitter":{"unique_users_count":11,"unique_users":["mtmdphd","sean_tiernan","Waldenstroms","WileyOnc_Hem","ymori117","sachi_1107","grpetersen1","MistyACallahan","rsbamagirl33","kittymama5500","cure_talk"],"posts_count":18},"facebook":{"unique_users_count":1,"unique_users":["1751700281710255"],"posts_count":1}},"selected_quotes":["Limiting early mortality: Do's don'ts in the management of NDMM - Gonsalves et al. #mmsm","iStopMM has the potential to eliminate late diagnosis, but until then this is a way to minimize early mortality!","Given the lack of adequate prospective data...routine TMP-SMX prophylaxis is not advised. #mmsm #SuppOnc","Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed ... #myeloma #cancer"],"citation":{"abstract":"In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population-level data indicates that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide \"do's and don'ts\" management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM-related complications. This article is protected by copyright. All rights reserved.","altmetric_jid":"4f6fa60a3cf058f610006979","authors":["Gonsalves, Wilson I.","Godby, Kelly","Kumar, Shaji K.","Costa, Luciano J.","Gonsalves, Wilson I","Kumar, Shaji K","Costa, Luciano J"],"doi":"10.1002\/ajh.24129","endpage":"108","first_seen_on":"2015-07-28T03:11:05+00:00","funders":["niehs"],"isbns":[],"issns":["1096-8652"],"issue":"1","journal":"American Journal of Hematology","last_mentioned_on":1474011614,"links":["http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24129\/abstract;jsessionid=6586EB241E6EF21F1A8EF1ED4EF33886.f04t01","http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24129\/abstract","http:\/\/onlinelibrary.wiley.com\/enhanced\/doi\/10.1002\/ajh.24129","http:\/\/onlinelibrary.wiley.com\/resolve\/doi?DOI=10.1002\/ajh.24129","http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24129\/full","http:\/\/onlinelibrary.wiley.com\/resolve\/doi?DOI=10.1002\/ajh.24129#.V9h9re1HD-o.twitter"],"pdf_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24129\/pdf","pmid":"26214377","pubdate":"2015-07-01T00:00:00+00:00","publisher_subjects":[{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"101","subjects":["hematology"],"title":"Limiting early mortality: Do&apos;s and don&apos;ts in the management of patients with newly diagnosed multiple myeloma","type":"article","volume":"91","mendeley_url":"http:\/\/www.mendeley.com\/research\/limiting-early-mortality-dos-donts-management-patients-newly-diagnosed-multiple-myeloma"},"altmetric_score":{"score":8.1,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":8.1},"context_for_score":{"all":{"total_number_of_other_articles":8389481,"mean":7.0670107241375,"rank":1096545,"this_scored_higher_than_pct":86,"this_scored_higher_than":7290392,"rank_type":"exact","sample_size":8389481,"percentile":86},"similar_age_3m":{"total_number_of_other_articles":230805,"mean":8.4918406440097,"rank":38838,"this_scored_higher_than_pct":83,"this_scored_higher_than":191849,"rank_type":"exact","sample_size":230805,"percentile":83},"this_journal":{"total_number_of_other_articles":1233,"mean":3.2873019480519,"rank":84,"this_scored_higher_than_pct":93,"this_scored_higher_than":1147,"rank_type":"exact","sample_size":1233,"percentile":93},"similar_age_this_journal_3m":{"total_number_of_other_articles":46,"mean":3.4133333333333,"rank":3,"this_scored_higher_than_pct":93,"this_scored_higher_than":43,"rank_type":"exact","sample_size":46,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":7,"researcher":1,"science_communicator":3},"users":{"twitter":{"cohorts":{"Scientists":1,"Members of the public":7,"Science communicators (journalists, bloggers, editors)":3}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Researcher":3,"Student  > Doctoral Student":1,"Other":3,"Student  > Master":1},"by_discipline":{"Medicine and Dentistry":8,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"US":4,"GB":1,"JP":1,"IN":1},"mendeley":{"BR":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/697803491314688001","license":"gnip","citation_ids":[4335096],"posted_on":"2016-02-11T15:24:51+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"697803491314688001"},{"url":"https:\/\/twitter.com\/sean_tiernan\/status\/625865926290731008","license":"datasift","citation_ids":[4335096],"posted_on":"2015-07-28T03:10:39+00:00","author":{"name":"Sean Tiernan","url":"http:\/\/mylifewithmyeloma.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1552303712\/Sean_G__normal.png","description":"Professional Photographer covering portraiture, fashion, glamour and product photography. I'm also a Cancer patient  having ongoing treatment for Myeloma.","id_on_source":"sean_tiernan","tweeter_id":"36006306","geo":{"lt":53.1905,"ln":-2.89189,"country":"GB"},"followers":411},"tweet_id":"625865926290731008"},{"url":"https:\/\/twitter.com\/mtmdphd\/status\/626468760224972800","license":"datasift","citation_ids":[4335096],"posted_on":"2015-07-29T19:06:06+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"626468760224972800"},{"url":"https:\/\/twitter.com\/mtmdphd\/status\/626470047754625024","license":"datasift","citation_ids":[4335096],"posted_on":"2015-07-29T19:11:13+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"626470047754625024"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/636183248951988225","license":"gnip","citation_ids":[4335096],"posted_on":"2015-08-25T14:28:00+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"636183248951988225"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/636183285824155648","license":"gnip","citation_ids":[4335096],"posted_on":"2015-08-25T14:28:09+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"636183285824155648"},{"url":"http:\/\/twitter.com\/Waldenstroms\/statuses\/636203400716120064","license":"gnip","rt":["mtmdphd"],"citation_ids":[4335096],"posted_on":"2015-08-25T15:48:05+00:00","author":{"name":"Mayo Waldenstroms","url":"http:\/\/www.mayoclinic.org\/waldenstrom-macroglobulinemia\/","image":"https:\/\/pbs.twimg.com\/profile_images\/3410057024\/b08b52502512e490bda682b8f5e38bdb_normal.png","description":"Waldenstrom macroglobulinemia (WM) or lymphoplasmacytic lymphoma; rare type of non-Hodgkin's lymphoma. Appts: AZ:800-446-2279, FL:904-953-0853, MN:507-284-5096","id_on_source":"Waldenstroms","tweeter_id":"37004480","geo":{"lt":"44.0220926935294","ln":"-92.4665581286087","country":"US"},"followers":309},"tweet_id":"636203400716120064"},{"url":"http:\/\/twitter.com\/WileyOnc_Hem\/statuses\/690249688050733056","license":"gnip","citation_ids":[4335096],"posted_on":"2016-01-21T19:08:44+00:00","author":{"name":"Wiley Onc & Hem","url":"https:\/\/www.facebook.com\/WileyOncologyNews","image":"https:\/\/pbs.twimg.com\/profile_images\/661213049999634432\/7kibW11y_normal.jpg","description":"Quality #oncology & #hematology research in a range of sub-disciplines including radiotherapy, breast disease, palliative care, psycho-oncology, transfusion...","id_on_source":"WileyOnc_Hem","tweeter_id":"987227946","geo":{"lt":null,"ln":null},"followers":531},"tweet_id":"690249688050733056"},{"url":"http:\/\/twitter.com\/ymori117\/statuses\/721188111808487425","license":"gnip","citation_ids":[4335096],"posted_on":"2016-04-16T04:06:59+00:00","author":{"name":"\u68ee\u3000\u52c7\u4e00","url":"http:\/\/twilog.org\/ymori117","image":"https:\/\/pbs.twimg.com\/profile_images\/848199682329255936\/8L7dBR04_normal.jpg","description":"\u9577\u91ce\u770c\u3067\u8840\u6db2\u5185\u79d1\u533b\u3092\u3057\u3066\u3044\u307e\u3059","id_on_source":"ymori117","tweeter_id":"128218698","geo":{"lt":36.65139,"ln":138.18111,"country":"JP"},"followers":2998},"tweet_id":"721188111808487425"},{"url":"http:\/\/twitter.com\/sachi_1107\/statuses\/721194470889226245","license":"gnip","rt":["ymori117"],"citation_ids":[4335096],"posted_on":"2016-04-16T04:32:15+00:00","author":{"name":"sachi","image":"https:\/\/pbs.twimg.com\/profile_images\/736668300751437824\/KBObYeh8_normal.jpg","description":"RT\u591a\u76ee\n\u52d5\u7269&\u5199\u771f&\u661f\u304c\u3059\u304d\/\uff26\uff13film","id_on_source":"sachi_1107","tweeter_id":"171133613","geo":{"lt":null,"ln":null},"followers":105},"tweet_id":"721194470889226245"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/762721646448967680","license":"gnip","citation_ids":[4335096],"posted_on":"2016-08-08T18:46:25+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"762721646448967680"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/775693124308008960","license":"gnip","citation_ids":[4335096],"posted_on":"2016-09-13T13:50:27+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"775693124308008960"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/775694368309145600","license":"gnip","citation_ids":[4335096],"posted_on":"2016-09-13T13:55:23+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15325},"tweet_id":"775694368309145600"},{"url":"http:\/\/twitter.com\/grpetersen1\/statuses\/775824130415493120","license":"gnip","citation_ids":[4335096],"posted_on":"2016-09-13T22:31:01+00:00","author":{"name":"Surviving Myeloma","url":"http:\/\/www.myelomasurvival.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3101334672\/a5f7d9a38331e080cc617369401e0cf4_normal.jpeg","description":"editor of http:\/\/www.myelomasurvival.com","id_on_source":"grpetersen1","tweeter_id":"523778748","geo":{"lt":30.33218,"ln":-81.65565,"country":"US"},"followers":1853},"tweet_id":"775824130415493120"},{"url":"http:\/\/twitter.com\/MistyACallahan\/statuses\/775828438712193024","license":"gnip","rt":["grpetersen1"],"citation_ids":[4335096],"posted_on":"2016-09-13T22:48:08+00:00","author":{"name":"Misty Callahan","url":"http:\/\/www.mistycallahan.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/905976318055129089\/AOsSSDKE_normal.jpg","description":"Traffic Reporter. @CSLIChicago Fellow, history nerd, book nerd, multiple myeloma activist. Opinions are my own. RT's \u2260 endorsements","id_on_source":"MistyACallahan","tweeter_id":"167510425","geo":{"lt":41.85003,"ln":-87.65005,"country":"US"},"followers":2997},"tweet_id":"775828438712193024"},{"url":"http:\/\/twitter.com\/rsbamagirl33\/statuses\/775831490835910656","license":"gnip","rt":["grpetersen1"],"citation_ids":[4335096],"posted_on":"2016-09-13T23:00:16+00:00","author":{"name":"rsbamagirl","image":"https:\/\/pbs.twimg.com\/profile_images\/544623981362307074\/PEYLYnv1_normal.jpeg","description":"Christian love my Lord..Love the PBR..Roll Tide","id_on_source":"rsbamagirl33","tweeter_id":"1110097921","geo":{"lt":null,"ln":null},"followers":1055},"tweet_id":"775831490835910656"},{"url":"http:\/\/twitter.com\/kittymama5500\/statuses\/775837785521528833","license":"gnip","rt":["grpetersen1"],"citation_ids":[4335096],"posted_on":"2016-09-13T23:25:17+00:00","author":{"name":"vivian kahan","image":"https:\/\/pbs.twimg.com\/profile_images\/2882436851\/eecca50cc967f917e1eebd1f875b8ac1_normal.jpeg","id_on_source":"kittymama5500","tweeter_id":"19928699","geo":{"lt":null,"ln":null},"followers":143},"tweet_id":"775837785521528833"},{"url":"http:\/\/twitter.com\/cure_talk\/statuses\/776687120215715840","license":"gnip","rt":["grpetersen1"],"citation_ids":[4335096],"posted_on":"2016-09-16T07:40:14+00:00","author":{"name":"Priya Menon","url":"http:\/\/www.curetalks.com","image":"https:\/\/pbs.twimg.com\/profile_images\/705014929137356800\/ybPD0HYI_normal.jpg","description":"Scientific Media Editor @CureTalks @TrialX @Appinformatics Cover #patientengagement & communications.Guest columnist @theweeklive","id_on_source":"cure_talk","tweeter_id":"129139322","geo":{"lt":13.08784,"ln":80.27847,"country":"IN"},"followers":1358},"tweet_id":"776687120215715840"}],"facebook":[{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1786154934931456&id=1751700281710255","license":"public","citation_ids":[4335096],"posted_on":"2016-08-08T23:56:04+00:00","summary":"This is an extremely important document which I am continuing to study. \"Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.\"\n\n http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24129\/full","author":{"name":"Diagnosed with Multiple Myeloma at 80","url":"https:\/\/www.facebook.com\/1751700281710255","facebook_wall_name":"Diagnosed with Multiple Myeloma at 80","image":"https:\/\/graph.facebook.com\/1751700281710255\/picture","id_on_source":"1751700281710255"}}]}}